Summary: Apply for a clinical trial for a predictive low glucose suspend (PLGS) system, why you should get the flu shot, and several probes into insulin pricing and profits seen by pharma companies.
Tandem PLGS Pivotal Trial: A Randomized Clinical Trial to Assess the Efficacy of Predictive Low Glucose Suspend Versus Sensor-augmented Pump Therapy in the Management of Type 1 Diabetes
There is currently a study recruiting people ages 6 and up to investigate an insulin pump and continuous glucose monitor (CGM) system with predictive low glucose suspend (PLGS). This is an important study, in my opinion, because they are including children in the participants. If you don’t already know, the FDA only gives approval for what the company submits. In other words, if a company doesn’t study it’s product on children, it won’t get FDA approval for use in children. This means that the device could be used “off label” by children, but sometimes there are more insurance hoops to jump through.
Predictive low glucose suspend is going to be a game changer for people with type 1 diabetes because the pump/CGM will head off low blood sugars by suspending basal insulin well before the blood sugar actually is low. This is one of the steps along the way to a complete automated artificial pancreas system.
Find out more about the “Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial.”
You should get the flu shot–even if it won’t keep you from getting sick
Immunizations are always a hot button topic, but getting a flu shot is really important for people with diabetes and those around them. People with diabetes are included in the group of high risk people because the affects of the flu can be far worse.
But I like to also look at the bigger picture: that it takes a herd mentality to keep people safe from diseases such as the flu. The more people who are immunized, the less likely it is to spread. And this is important for those people who cannot themselves get vaccinated.
Read more about this in the article “You should get the flu shot–even if it won’t keep you from getting sick” on Popular Science.
Several Probes Target Insulin Drug Pricing
“With the price of a crucial diabetes drug skyrocketing, at least five states and a federal prosecutor are demanding information from insulin manufacturers and the pharmaceutical industry’s financial middlemen about their business relationships and the soaring price of diabetes drugs.”
There is no question that the cost of insulin–and the profits seen by Eli Lilly, Novo Nordisk, and Sanofi–have increased dramatically in recent years. It’s a shame that we are beholden to these companies for life sustaining drugs because the appearance is that they are profiting from the life-or-death needs of people with diabetes.
I’m glad to see this topic in mainstream, national media.
Read “Several Probes Target Insulin Drug Pricing” on NBC News’ website.
You Might Also Like…
More 3 Little Diabetes Things posts